We found that the combination of low SerpinB2, high NOS2, and low CD206 mRNA expression was associated with favorable DFS in patients with breast cancer, suggesting that rather than focusing on a single gene biomarker, a combined multigene marker may have more powerful prognostic or predictive value. This evidence concerns the gene NOS2 and breast cancer.